RxDoctor Payments Data

Karen Ann Rayos, MD

Family Medicine · Modesto, CANPI 1114300209

Payments from drug & device makers

$1,436in general payments, 2019–2025

Across 37 payments — averaging $38.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$314
  • Johnson & Johnson$257
  • Otsuka America Pharmaceutical, Inc.$209
  • Gilead$107
  • Sanofi-aventis U.S. LLC$105
  • Mayne Pharma Commercial LLC$105
  • plus $338 from 7 others

What the payments were for

  • Food & beverage$1,39197%
  • Education$453%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,436 in reported general payments places this provider in the 75th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$14,968
Medicare patients
38
Services billed
145

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate11$12,135
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog12$3,307
BreynaBudesonide/Formoterol Fumarate13$1,994
Atorvastatin Calcium72$970
Albuterol Sulfate HfaAlbuterol Sulfate16$650
Levothyroxine Sodium30$428
Baclofen23$395
Lisinopril45$314
Metformin Hcl31$234
Tamsulosin Hcl16$160
Amlodipine Besylate29$155
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen13$154
Gabapentin14$113
Hydralazine Hcl14$95
Furosemide21$90

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia$51$12,13511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 10,533 family medicine providers in California.

Other family medicine in Modesto

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →